In order to encourage the foundry science and technology staff of our country to actively participate in the foundry academic activities, and in order to promote the development of China foundry technology and the imp...In order to encourage the foundry science and technology staff of our country to actively participate in the foundry academic activities, and in order to promote the development of China foundry technology and the improvement of China foundry academic levels, the second stage work (final judgement) of the 6th FOSECO Cup Excellent Foundry Papers organized by Foundry Institution of Chinese Mechanical Engineering Society (FICMES) was carried out in Chengdu, Sichuan Province on May 17-20, 2004. Two gold award papers and 10 silver award papers were awarded, and the other 34 papers recommended into the final judgement were nominated as excellent papers.展开更多
Underscoring its commitment to innovation,the European Committee of Textile Machinery Manufacturers(CEMATEX)will continue to promote excellence in research and development at ITMA 2019.The CEMATEX Research&Innovat...Underscoring its commitment to innovation,the European Committee of Textile Machinery Manufacturers(CEMATEX)will continue to promote excellence in research and development at ITMA 2019.The CEMATEX Research&Innovation Grant will help defray participation cost of eligible educational展开更多
Chronic hepatitis B(CHB)virus infection is a global public health problem,affecting more than 400 million people worldwide.The clinical spectrum is wide,ranging from a subclinical inactive carrier state,to progressive...Chronic hepatitis B(CHB)virus infection is a global public health problem,affecting more than 400 million people worldwide.The clinical spectrum is wide,ranging from a subclinical inactive carrier state,to progressive chronic hepatitis,cirrhosis,decompensation,and hepatocellular carcinoma.However,complications of hepatitis B virus(HBV)-related chronic liver disease may be reduced by viral suppression.Current international guidelines recommend first-line treatment of CHB infection with pegylated interferon,entecavir,or tenofovir,but the optimal treatment for an individualpatient is controversial.The indications for treatment are contentious,and increasing evidence suggests that HBV genotyping,as well as serial on-treatment measurements of hepatitis B surface antigen and HBV DNA kinetics should be used to predict antiviral treatment response.The likelihood of achieving a sustained virological response is also increased by extending treatment duration,and using combination therapy.Hence the paradigm for treatment of CHB is constantly evolving.This article summarizes the different indications for treatment,and systematically reviews the evidence for the efficacy of various antiviral agents.It further discusses the shortcomings of current guidelines,use of rescue therapy in drug-resistant strains of HBV,and highlights the promising clinical trials for emerging therapies in the pipeline.This concise overview presents an updated practical approach to guide the clinical management of CHB.展开更多
文摘In order to encourage the foundry science and technology staff of our country to actively participate in the foundry academic activities, and in order to promote the development of China foundry technology and the improvement of China foundry academic levels, the second stage work (final judgement) of the 6th FOSECO Cup Excellent Foundry Papers organized by Foundry Institution of Chinese Mechanical Engineering Society (FICMES) was carried out in Chengdu, Sichuan Province on May 17-20, 2004. Two gold award papers and 10 silver award papers were awarded, and the other 34 papers recommended into the final judgement were nominated as excellent papers.
文摘Underscoring its commitment to innovation,the European Committee of Textile Machinery Manufacturers(CEMATEX)will continue to promote excellence in research and development at ITMA 2019.The CEMATEX Research&Innovation Grant will help defray participation cost of eligible educational
基金Supported by Collaborative Research Fund(CUHK3/CRF/12RHKU3/CRF11R)of the Research Grant Council Hong Kong+2 种基金National Basic Research Program of China,973 Program,No.2013CB531401CUHK Focused Investments Scheme B to HY LanTheme-based Research Scheme of the Hong Kong Re-search Grants Council,No.T12-403-11
文摘Chronic hepatitis B(CHB)virus infection is a global public health problem,affecting more than 400 million people worldwide.The clinical spectrum is wide,ranging from a subclinical inactive carrier state,to progressive chronic hepatitis,cirrhosis,decompensation,and hepatocellular carcinoma.However,complications of hepatitis B virus(HBV)-related chronic liver disease may be reduced by viral suppression.Current international guidelines recommend first-line treatment of CHB infection with pegylated interferon,entecavir,or tenofovir,but the optimal treatment for an individualpatient is controversial.The indications for treatment are contentious,and increasing evidence suggests that HBV genotyping,as well as serial on-treatment measurements of hepatitis B surface antigen and HBV DNA kinetics should be used to predict antiviral treatment response.The likelihood of achieving a sustained virological response is also increased by extending treatment duration,and using combination therapy.Hence the paradigm for treatment of CHB is constantly evolving.This article summarizes the different indications for treatment,and systematically reviews the evidence for the efficacy of various antiviral agents.It further discusses the shortcomings of current guidelines,use of rescue therapy in drug-resistant strains of HBV,and highlights the promising clinical trials for emerging therapies in the pipeline.This concise overview presents an updated practical approach to guide the clinical management of CHB.
